VYVGART ® SC is first and only neonatal Fc receptor blocker approved to treat CIDP Authorization is based on global ADHERE study, the largest clinical trial in CIDP to date First novel, targeted ...
12d
Is Health Canada's Approval of VYVGART SC Transforming the Investment Case for argenx (ENXTBR:ARGX)?
On November 5, 2025, argenx SE announced that Health Canada approved VYVGART SC (efgartigimod alfa injection) as a monotherapy for adults with active chronic inflammatory demyelinating polyneuropathy ...
News Medical on MSN
State-of-the-art multimodal imaging and therapeutic strategies in radiation-induced brain injury
Radiotherapy remains one of the essential treatment modalities for brain gliomas, brain metastases, pediatric neuroblastomas, ...
Findings from the post-hoc analysis of LIBERTY-CD study indicates efficacy of ZYMFENTRA® (subcutaneous infliximab) regardless ...
HK Innoen is accelerating the expansion of its portfolio in geriatric and metabolic diseases by launching full-scale development of a treatment for ...
After being told he might not walk for two years, the longtime Little League football coach fought through treatment to ...
CNW/ - argenx SE (EURONEXT: ARGX) (Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today announced that Health Canada ...
While documenting life on Hawaii’s Big Island, photographer Josh Cogan follows one man’s path toward reconnection—where food, ...
The S&P 1500 Health Care Index advanced 4.0% in the third quarter, underperforming the S&P 500, which gained 8.1%. Read more ...
The good news is that, with significant late-stage pipeline activity, new early-stage projects, and continued strong ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback